Anika Therapeutics logo
Anika Therapeutics
ANIK | NASDAQ
Chart Builder DCF Calculator
$12.92
-$0.48 (-3.58%)
At close: Nov 16, 2026, 4:00 PM ET
$12.92
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Anika Therapeutics Company Profile

Company profile explained

Company Profile

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Key Executives

Name Position
Stephen D. Griffin President, Principal Financial Officer, CEO & Director
Ben Joseph Senior Vice President of Commercial
Cheryl Renee Blanchard Executive Chair
Ian W. McLeod Senior VP, Chief Accounting Officer & Treasurer
Lisa Funiciello VP & Chief Human Resources Officer
Matthew Hall Executive Director of Corporate Development & Investor Relations
Mira Leiwant Senior Vice President of Regulatory, Quality & Clinical Affairs

Latest SEC Filings

Date Type Title
Aug 07, 2026 144 Filing
Aug 05, 2026 4 Filing
Jul 31, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 29, 2026 S-8 Filing
Jul 29, 2026 10-Q Quarterly Report
Jul 29, 2026 8-K Current Report
Jul 17, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 14, 2026 8-K Current Report
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
View All SEC Filings ➞
Anika Therapeutics
Anika Therapeutics logo
Country United States
IPO Date May 3, 1993
Industry Medical - Specialties
Sector Healthcare
Employees 235
CEO Stephen D. Griffin

Contact Details

32 Wiggins Avenue Bedford, Massachusetts 01730 United States

Stock Details

Ticker Symbol ANIK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000898437
CUSIP Number 035255108
ISIN Number US0352551081
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.